Cargando…

Plasticity in growth behavior of patients’ acute myeloid leukemia stem cells growing in mice

Detalles Bibliográficos
Autores principales:	Ebinger, Sarah, Zeller, Christina, Carlet, Michela, Senft, Daniela, Bagnoli, Johannes W., Liu, Wen-Hsin, Rothenberg-Thurley, Maja, Enard, Wolfgang, Metzeler, Klaus H., Herold, Tobias, Spiekermann, Karsten, Vick, Binje, Jeremias, Irmela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2020
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716350/ https://www.ncbi.nlm.nih.gov/pubmed/33256387 http://dx.doi.org/10.3324/haematol.2019.226282

Ejemplares similares

An Advanced Preclinical Mouse Model for Acute Myeloid Leukemia Using Patients' Cells of Various Genetic Subgroups and In Vivo Bioluminescence Imaging
por: Vick, Binje, et al.
Publicado: (2015)

Loss of KDM6A confers drug resistance in acute myeloid leukemia
por: Stief, Sophie M., et al.
Publicado: (2019)

Adverse stem cell clones within a single patient’s tumor predict clinical outcome in AML patients
por: Zeller, Christina, et al.
Publicado: (2022)

Prime-seq, efficient and powerful bulk RNA sequencing
por: Janjic, Aleksandar, et al.
Publicado: (2022)

Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia
por: Reiter, K, et al.
Publicado: (2018)

Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
por: Rausch, Christian, et al.
Publicado: (2023)

Loss-of-function mutations in the histone methyltransferase EZH2 promote chemotherapy resistance in AML
por: Kempf, Julia M., et al.
Publicado: (2021)

Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia
por: Rothenberg-Thurley, Maja, et al.
Publicado: (2018)

A Novel Anti-CD73 Antibody That Selectively Inhibits Membrane CD73 Shows Antitumor Activity and Induces Tumor Immune Escape
por: Kellner, Markus, et al.
Publicado: (2022)

In vivo inducible reverse genetics in patients’ tumors to identify individual therapeutic targets
por: Carlet, Michela, et al.
Publicado: (2021)

Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older
por: Prassek, Victoria V., et al.
Publicado: (2018)

ZBTB7A prevents RUNX1-RUNX1T1-dependent clonal expansion of human hematopoietic stem and progenitor cells
por: Redondo Monte, Enric, et al.
Publicado: (2020)

P446: COMPREHENSIVE CHARACTERIZATION OF DIFFERENTIAL GENE EXPRESSION AND ISOFORM USAGE IN SPLICING FACTOR-MUTATED ACUTE MYELOID LEUKEMIA USING LONG-READ SEQUENCING
por: Thieme, Susanne, et al.
Publicado: (2023)

Allelic Imbalance of Recurrently Mutated Genes in Acute Myeloid Leukaemia
por: Batcha, Aarif M. N., et al.
Publicado: (2019)

Anti-leukemic effects of the V-ATPase inhibitor Archazolid A
por: Zhang, Siwei, et al.
Publicado: (2015)

A reporter system for enriching CRISPR/Cas9 knockout cells in technically challenging settings like patient models
por: Liu, Wen-Hsin, et al.
Publicado: (2021)

Mediation analysis reveals common mechanisms of RUNX1 point mutations and RUNX1/RUNX1T1 fusions influencing survival of patients with acute myeloid leukemia
por: Hornung, Roman, et al.
Publicado: (2018)

A clinically applicable gene expression–based score predicts resistance to induction treatment in acute myeloid leukemia
por: Moser, Christian, et al.
Publicado: (2021)

Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
por: Herold, Tobias, et al.
Publicado: (2020)

P457: COMPLEX CARYOTYPE IS AN INDEPENDENT RISK FACTOR IN TP53-MUTATED AML
por: Rausch, Christian, et al.
Publicado: (2023)

P434: MYELODYSPLASIA-RELATED MUTATIONS IN THE NEW ELN CLASSIFICATION: DOES CLONAL SIZE PLAY A ROLE?
por: Rausch, Christian, et al.
Publicado: (2023)

Clonal heterogeneity of FLT3-ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia
por: Schranz, Katrin, et al.
Publicado: (2018)

A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia
por: Herold, Tobias, et al.
Publicado: (2018)

Inducible transgene expression in PDX models in vivo identifies KLF4 as a therapeutic target for B-ALL
por: Liu, Wen-Hsin, et al.
Publicado: (2020)

P1402: ALTERATIONS OF HUMAN BONE MARROW NICHE IN CLONAL HEMATOPOIESIS AND AML
por: Dragieva, Y., et al.
Publicado: (2022)

Targeting the endoplasmic reticulum-mitochondria interface sensitizes leukemia cells to cytostatics
por: Koczian, Fabian, et al.
Publicado: (2019)

Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia
por: Alachkar, Houda, et al.
Publicado: (2014)

Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia
por: Koschade, Sebastian E., et al.
Publicado: (2022)

X‐linked inhibitor of apoptosis protein represents a promising therapeutic target for relapsed/refractory ALL
por: Carlet, Michela, et al.
Publicado: (2022)

Correction: Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia
por: Koschade, Sebastian E., et al.
Publicado: (2022)

P328: CHARACTERIZATION OF A DUX4-R INHIBITOR AS A POSSIBLE TREATMENT FOR ACUTE LYMPHOBLASTIC LEUKEMIA
por: Salomè, Mara, et al.
Publicado: (2023)

In vivo PDX CRISPR/Cas9 screens reveal mutual therapeutic targets to overcome heterogeneous acquired chemo-resistance
por: Wirth, Anna-Katharina, et al.
Publicado: (2022)

Modeling early treatment response in AML from cell-free tumor DNA
por: Wang, Dantong, et al.
Publicado: (2023)

SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells
por: Tahk, Siret, et al.
Publicado: (2021)

Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in FLT3-ITD AML with concurrent epigenetic mutations
por: Garz, Anne-Kathrin, et al.
Publicado: (2017)

Germline SNPs previously implicated as prognostic biomarkers do not associate with outcomes in intensively treated AML
por: Batcha, Aarif M. N., et al.
Publicado: (2022)

The new and recurrent FLT3 juxtamembrane deletion mutation shows a dominant negative effect on the wild-type FLT3 receptor
por: Sandhöfer, Nadine, et al.
Publicado: (2016)

Enforced sialyl‐Lewis‐X (sLeX) display in E‐selectin ligands by exofucosylation is dispensable for CD19‐CAR T‐cell activity and bone marrow homing
por: Sánchez‐Martínez, Diego, et al.
Publicado: (2021)

Characterization of Rare, Dormant, and Therapy-Resistant Cells in Acute Lymphoblastic Leukemia
por: Ebinger, Sarah, et al.
Publicado: (2016)

Combined proteomics and CRISPR‒Cas9 screens in PDX identify ADAM10 as essential for leukemia in vivo
por: Bahrami, Ehsan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tmuec7gb70cmk7v2megahb0a40